STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] OptiNose, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

OptiNose, Inc. filing discloses that Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon report beneficial ownership of 0 common shares (0.0%) of OptiNose common stock. The filing lists no sole or shared voting power and no sole or shared dispositive power for any reporting person.

The statement identifies Rosalind Advisors as an adviser and Salamon and Aharon as portfolio managers and includes a certification that the securities are held in the ordinary course of business and were not acquired to influence control; ownership is reported as 5% or less.

Positive
  • Transparent disclosure showing 0 shares (0.0%) beneficial ownership by the reporting persons
  • Certification included that securities are held in the ordinary course and not to influence control
Negative
  • No voting or dispositive power reported by the filers — they hold 0 shares (0.0%)

Insights

TL;DR: Reporting parties disclose zero ownership and no voting or dispositive power; impact on equity holders is neutral.

The Schedule 13G/A shows 0 shares (0.0%) beneficially owned by Rosalind Advisors, Rosalind Master Fund, Steven Salamon and Gilad Aharon. All entries for sole and shared voting and dispositive power are zero and the filing indicates ownership of 5% or less. This is a routine disclosure from an adviser and portfolio managers; it confirms no equity stake or control intent from the named parties.

TL;DR: No reported stake and an explicit certification that holdings are not for control; no governance influence from these filers.

The document identifies the reporting parties and their roles and certifies that the securities are held in the ordinary course and not to change or influence control. With 0 shares (0.0%) and no voting/dispositive power recorded, there is no material governance impact from these entities or individuals based on this filing.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/11/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/11/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/11/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/11/2025

FAQ

Who filed the Schedule 13G/A for OPTN?

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon are named as the reporting persons.

How many OptiNose (OPTN) common shares do the reporting persons beneficially own?

0 shares (0.0%).

Do the reporting persons have voting or dispositive power over OptiNose shares?

No. The filing reports zero sole and zero shared voting and dispositive power for each reporting person.

Does the filing indicate the reporting persons seek to influence control of OptiNose?

No. The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control.

Is the ownership reported above or below the 5% threshold?

Below 5%. The filing indicates ownership of 5% or less.

What roles do Steven Salamon and Gilad Aharon have according to the filing?

They are identified as portfolio managers associated with Rosalind Advisors, the adviser to Rosalind Master Fund.
Optinose

NASDAQ:OPTN

OPTN Rankings

OPTN Latest News

OPTN Latest SEC Filings

OPTN Stock Data

96.41M
9.47M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
US
YARDLEY